CONFERENCE SUMMARY | CONTINUING MEDICAL EDUCATION

1

The Advances in Neurological Therapeutics conference took place on September 17th, 2011 at the Lou Ruvo Center for Brain Health (LRCBH) in Las Vegas, NV. The purpose of the conference was to advance the understanding of neurological therapeutics and provide instruction to regional practitioners regarding diagnosis and treatment of complex neurodegenerative disorders including dementia—particularly Alzheimer’s disease and Rapidly Progressive Dementias, Parkinson’s disease, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis. By providing the latest advances in diagnosis and treatment, we sought to help practitioners (including family and primary care physicians, neurologists, psychiatrists, physician assistants, nurse practitioners, and physical therapists) effectively manage patients in the earliest stages of these diseases and thereby raise the standards of patient prognosis and care.

Clockwise left to right: Dr. Jeffrey Cummings, Conference Chair and Director of the LRCBH; Participants during the conference; Dr. Ryan Walsh, Director of the PD and Movement Disorders Program, LRCBH; Dr. Dylan Wint, Director of Education in Neurodegeneration, LRCBH; Dr. Erik Pioro, Director of the Section of ALS and Related Disorders, Cleveland Clinic Main Campus.

CONFERENCE SUMMARY | CONTINUING MEDICAL EDUCATION

2

A total of 100 participants registered for the event.

Physicians = 48 PhD = 4 PharmD = 2 MPH = 1 LPN/APRN/RN = 5 MISC Degrees = 15 PT/DPT/PTA/MPT/OT = 25

Evaluations:

Evaluations, for AMA/PRA Category 1 Credits (Physicians/PAs/LPNs, etc.), are being completed online on “MYCME”, a Cleveland Clinic CME website. Below are the actual results, to date.

Activity Title: Advances in Neurological Therapeutics

Activity #: 020756

Activity Type: Live

Activity Date: 9/17/2011

Activity Credit Available: 6.0

Date of Report: 11/2/2011 2:05:44 PM

Total Evaluations: 39

Total Credits Claimed: 226.5

What was the overall opinion of the activity: Excellent: Good:

Satisfactory: Poor:

30 6 1 0

81.1 16.2 2.7 0.0

Objective 1: Identify early signs and symptoms of neurological diseases. Met: Not Met:

39 0

100.0 0.0

Objective 2: Utilize advances in neurological imaging to better diagnose neurological diseases.

Met: Not Met:

39 0

100.0 0.0

Objective 3: Recognize and better manage the variety of behavioral complications of neurological illnesses.

Met: Not Met:

39 0

100.0 0.0

Objective 4: Distinguish major advances in the pharmacological therapies of neurological disorders.

Met: Not Met:

39 0

100.0 0.0

Objective 5: Anticipate the major drug-drug interactions. Met: Not Met:

36 2

94.7 5.3

Objective 6: Manage combination therapies in order to optimize patient function.

Met: Not Met:

37 1

97.4 2.6

Quality of educational content: Excellent: Good:

Satisfactory:

35 3 1

89.7 7.7 2.6

0

5

10

15

20

25

30

35

40

100 Participants

100 Participants registered for the event

Physicians

PhD

PharmD

MPH

LPN/APRN/RN

Misc Degrees

PT/DPT/PTA/MPT/OT

CONFERENCE SUMMARY | CONTINUING MEDICAL EDUCATION

3

PT Evaluations out of 27 respondents.

PT’s apply for CEUs, (0.6) so there was a paper evaluation process. The questions included the following queries: Facility conducive to learning; Content of syllabus/handout material; Time for questions; Length of course for content; Overall course management. Results: 5 out of 5 Excellent: 14 – The rest Very Good 4 out of 5 Excellent: 2 – One Very Good – One Good 3 out of 5 Excellent: 5 – Four Very Good – One Good 2 out of 5 Excellent: 3 – The rest Very Good 1 out of 5 Excellent: 1 – The rest Very Good 5 out of 5 Very Good: 1 4 out of 5 Very Good – The other Good A majority of the evaluation downgrades from Excellent to Very Good/Good, cite “Appropriate time for questions” and “Length of course for content” as areas that can be approved.

Poor: 0 0.0

Quality of design and organization: Excellent: Good:

Satisfactory: Poor:

32 5 1 0

84.2 13.2 2.6 0.0

Ease of use: Excellent: Good:

Satisfactory: Poor:

34 4 1 0

87.2 10.3 2.6 0.0

Please rate the degree to which this activity met the ACCME requirement that CME activities must be free of commerical bias for or against a specific product:

Excellent: Good:

Satisfactory: Poor:

31 6 0 1

81.6 15.8 0.0 2.6

Overall was the activity satisfactorily free from commercial bias?: Yes: No:

37 2

94.9 5.1

How much of this content was new to you?: Almost All: Almost 75%: Almost 50%: Almost 25%:

Almost None:

6 10 12 8 2

15.8 26.3 31.6 21.1 5.3

Compared with other CME activities, this activity was: Better Than Avg: Average:

Below Average:

34 4 0

89.5 10.5 0.0

Would you recommend this CME activity to colleagues?: Yes: No:

34 1

97.1 2.9

CONFERENCE SUMMARY | CONTINUING MEDICAL EDUCATION

4

Audience Response System

There were pre and post-conference questions to determine whether learning occurred during the course of the conference. Using an Audience Response System, through Turning Technologies, the post-polling results show that learning did occur on 94.4% of the targeted content. (Please see the attached.)

Budget

A total of $83,315 was raised for the Advances in Neurological Conference Baxter $ 15,000.00

Biogen Idec $ 15,000.00

TEVA Neuroscience $ 25,000.00

Elan Pharmaceuticals $ 15,000.00

Martek Biosciences $ 1,000.00

Total Grants $ 71,000.00

Total Exhibits $ 6,000.00

Total Registration Fees $ 6,315.00

Total Revenue $ 83,315.00

Expenses totaled $83,844.90. The balance is -$529.90.